Psychedelic drug company Mind Medicine Inc. (MindMed) (NASDAQ: MNMD) published its 2025 Investor Presentation this week with ...

Robert Barrow, the Chief Executive Officer of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), a $502 million market cap company that has delivered an impressive 108% return... Mark Sullivan ...

Mind Medicine (MindMed) MNMD is developing its lead pipeline ... Some better-ranked stocks from the biotech sector are Castle Biosciences, Inc. CSTL, CytomX Therapeutics CTMX and Spero ...

1 Day MNMD -6.28% DJIA 0.86% Russell 2K 0.24% Health Care/Life Sciences 0.43% ...

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) has earned an average recommendation of “Buy” from the eleven research firms that are covering the firm, MarketBeat.com reports.

Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders ...

Mind Medicine (MindMed) MNMD is developing its lead pipeline candidate, MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized form of lysergide D-tartrate (LSD), for the ...

NEW YORK, December 19, 2024--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company ...